227 related articles for article (PubMed ID: 35122055)
21. LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization.
Hu J; Dong F; He Y; Xia X; Cheng F; Chen S; Hou X; Zhang P; Liu G; Li Y; Gao Q; Dong M; Li T; Li W; Xiao Q; Li X; Yu X; Xi G; Guo D; Wu X; Wang B
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096529
[TBL] [Abstract][Full Text] [Related]
22. The β-Secretase BACE1 in Alzheimer's Disease.
Hampel H; Vassar R; De Strooper B; Hardy J; Willem M; Singh N; Zhou J; Yan R; Vanmechelen E; De Vos A; Nisticò R; Corbo M; Imbimbo BP; Streffer J; Voytyuk I; Timmers M; Tahami Monfared AA; Irizarry M; Albala B; Koyama A; Watanabe N; Kimura T; Yarenis L; Lista S; Kramer L; Vergallo A
Biol Psychiatry; 2021 Apr; 89(8):745-756. PubMed ID: 32223911
[TBL] [Abstract][Full Text] [Related]
23. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
Vassar R
J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
[TBL] [Abstract][Full Text] [Related]
24. Activation of the Wnt/β-catenin pathway represses the transcription of the β-amyloid precursor protein cleaving enzyme (BACE1) via binding of T-cell factor-4 to BACE1 promoter.
Parr C; Mirzaei N; Christian M; Sastre M
FASEB J; 2015 Feb; 29(2):623-35. PubMed ID: 25384422
[TBL] [Abstract][Full Text] [Related]
25. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.
Barão S; Moechars D; Lichtenthaler SF; De Strooper B
Trends Neurosci; 2016 Mar; 39(3):158-169. PubMed ID: 26833257
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and evaluation of 2-amino-imidazol-4-one derivatives as potent β-site amyloid precursor protein cleaving enzyme 1 (BACE-1) inhibitors.
Fan TY; Wu WY; Yu SP; Zhong Y; Zhao C; Chen M; Li HM; Li NG; Chen Z; Chen S; Sun ZH; Duan JA; Shi ZH
Bioorg Med Chem Lett; 2019 Dec; 29(24):126772. PubMed ID: 31711785
[TBL] [Abstract][Full Text] [Related]
27. Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo.
Hirata-Fukae C; Sidahmed EH; Gooskens TP; Aisen PS; Dewachter I; Devijver H; Van Leuven F; Matsuoka Y
Neurosci Lett; 2008 Apr; 435(3):186-9. PubMed ID: 18343582
[TBL] [Abstract][Full Text] [Related]
28. An Overview of β-Amyloid Cleaving Enzyme 1 (BACE1) in Alzheimer's Disease Therapy: Elucidating its Exosite-Binding Antibody and Allosteric Inhibitor.
Ugbaja SC; Lawal MM; Kumalo HM
Curr Med Chem; 2022; 29(1):114-135. PubMed ID: 34102967
[TBL] [Abstract][Full Text] [Related]
29. BACE1 as a therapeutic target in Alzheimer's disease: rationale and current status.
Evin G; Hince C
Drugs Aging; 2013 Oct; 30(10):755-64. PubMed ID: 23842796
[TBL] [Abstract][Full Text] [Related]
30. The influence of BACE1 on macrophage recruitment and activity in the injured peripheral nerve.
Fissel JA; Farah MH
J Neuroinflammation; 2021 Mar; 18(1):71. PubMed ID: 33722254
[TBL] [Abstract][Full Text] [Related]
31. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
Kennedy ME; Stamford AW; Chen X; Cox K; Cumming JN; Dockendorf MF; Egan M; Ereshefsky L; Hodgson RA; Hyde LA; Jhee S; Kleijn HJ; Kuvelkar R; Li W; Mattson BA; Mei H; Palcza J; Scott JD; Tanen M; Troyer MD; Tseng JL; Stone JA; Parker EM; Forman MS
Sci Transl Med; 2016 Nov; 8(363):363ra150. PubMed ID: 27807285
[TBL] [Abstract][Full Text] [Related]
32. Identification of potential lead compounds against BACE1 through in-silico screening of phytochemicals of Medhya rasayana plants for Alzheimer's disease management.
Nadh AG; Revikumar A; Sudhakaran PR; Nair AS
Comput Biol Med; 2022 Jun; 145():105422. PubMed ID: 35354103
[TBL] [Abstract][Full Text] [Related]
33. BACE1 elevation engendered by GGA3 deletion increases β-amyloid pathology in association with APP elevation and decreased CHL1 processing in 5XFAD mice.
Kim W; Ma L; Lomoio S; Willen R; Lombardo S; Dong J; Haydon PG; Tesco G
Mol Neurodegener; 2018 Feb; 13(1):6. PubMed ID: 29391027
[TBL] [Abstract][Full Text] [Related]
34. A Novel Compound YS-5-23 Exhibits Neuroprotective Effect by Reducing β-Site Amyloid Precursor Protein Cleaving Enzyme 1's Expression and H
Cheng C; Zheng N; Sun D; Fang W; Zheng L; Song W; Huang J
Neurochem Res; 2020 Sep; 45(9):2113-2127. PubMed ID: 32556702
[TBL] [Abstract][Full Text] [Related]
35. The BACE1-Specific DNA Aptamer A1 Rescues Amyloid-β Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease.
Liang ZM; Peng YH; Chen Y; Long LL; Luo HJ; Chen YJ; Liang YL; Tian YH; Li SJ; Shi YS; Zhang XM
Nucleic Acid Ther; 2019 Dec; 29(6):359-366. PubMed ID: 31513457
[TBL] [Abstract][Full Text] [Related]
36. Alternative Selection of β-Site APP-Cleaving Enzyme 1 (BACE1) Cleavage Sites in Amyloid β-Protein Precursor (APP) Harboring Protective and Pathogenic Mutations within the Aβ Sequence.
Kimura A; Hata S; Suzuki T
J Biol Chem; 2016 Nov; 291(46):24041-24053. PubMed ID: 27687728
[TBL] [Abstract][Full Text] [Related]
37. BACE1 Inhibitors for Alzheimer's Disease: The Past, Present and Any Future?
Bazzari FH; Bazzari AH
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557955
[TBL] [Abstract][Full Text] [Related]
38. Camelid heavy chain only antibody fragment domain against β-site of amyloid precursor protein cleaving enzyme 1 inhibits β-secretase activity in vitro and in vivo.
Dorresteijn B; Rotman M; Faber D; Schravesande R; Suidgeest E; van der Weerd L; van der Maarel SM; Verrips CT; El Khattabi M
FEBS J; 2015 Sep; 282(18):3618-31. PubMed ID: 26147692
[TBL] [Abstract][Full Text] [Related]
39. Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease.
Chen CH; Zhou W; Liu S; Deng Y; Cai F; Tone M; Tone Y; Tong Y; Song W
Int J Neuropsychopharmacol; 2012 Feb; 15(1):77-90. PubMed ID: 21329555
[TBL] [Abstract][Full Text] [Related]
40. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
